ENDV Stock Surges 9900% on May 7, 2026 – Endonovo Therapeutics Gains

ENDV stock delivered a stunning 9900% gain on May 7, 2026, trading at $0.0001 USD on the PNK exchange. Endonovo Therapeutics, Inc., a biotechnology company specializing in non-invasive Electroceutical medical devices, saw trading volume reach 500,000 shares, significantly above its average of 873,858. The dramatic spike marks an unusual move for the penny stock, which has struggled with negative earnings and a market cap of just $15,938. Investors tracking ENDV stock should understand the underlying fundamentals before reacting to extreme price swings. This biotech firm develops the SofPulse device for treating soft tissue injuries, chronic wounds, and various medical conditions through regenerative medicine technology.

ENDV Stock Performance and Price Movement

ENDV stock’s 9900% surge represents an extreme intraday move that demands careful analysis. The stock climbed from a previous close of $0.000001 to $0.0001, though trading remained confined to this single price level throughout the session. Year-to-date performance shows a 50% decline, while the three-year chart reflects a devastating 99.66% loss. The stock trades well below its 50-day average of $0.000088 and its 200-day average of $0.0001056.

Volume activity provides context for the price movement. Trading volume of 500,000 shares exceeded the 30-day average of 873,858 by a relative volume of 3.43x. However, the stock’s extreme illiquidity and minimal market cap of $15,938 mean even modest share purchases can trigger outsized percentage moves. The day’s high and low both settled at $0.0001, indicating the stock traded in a narrow band despite the percentage gain.

Endonovo Therapeutics Business Model and Technology

Endonovo Therapeutics develops non-invasive Electroceutical medical devices for regenerative medicine applications. The company’s flagship product, SofPulse, targets soft tissue injuries, chronic wounds, post-operative pain, and edema through electromagnetic pulse technology. Founded in 2008 and headquartered in Woodland Hills, California, the company operates in the Healthcare sector within the Biotechnology industry.

The company’s technology extends beyond wound care. Endonovo’s Electroceuticals platform addresses inflammation, cardiovascular diseases, chronic kidney disease, liver disease, and non-alcoholic steatohepatitis. The device also shows potential for peripheral artery disease, ischemic stroke, and central nervous system disorders including traumatic brain injury, concussions, and multiple sclerosis. With only one full-time employee listed, the company operates as a lean biotech venture focused on device development and commercialization.

Financial Health and Valuation Metrics

ENDV stock presents extreme financial challenges reflected in its valuation metrics. The company reports negative earnings per share of -$0.01 and a negative book value per share of -$0.0253. Working capital stands at -$27.7 million, indicating the company burns cash and carries significant liabilities. The current ratio of 0.0006 reveals severe liquidity constraints, with current liabilities far exceeding current assets.

Key metrics paint a concerning picture for investors. Revenue per share remains at zero, while net income per share sits at -$0.0016. The debt-to-assets ratio of 384.26 shows liabilities dwarf equity. However, operating cash flow per share of $0.000094 and free cash flow per share of $0.000094 suggest minimal operational activity. Track ENDV on Meyka for real-time updates on these deteriorating fundamentals.

Market Sentiment and Trading Activity

Market sentiment toward ENDV stock remains decidedly negative according to Meyka AI’s analysis. The company receives a C- rating with a “Strong Sell” recommendation based on comprehensive financial analysis. Multiple valuation metrics score at the lowest level: DCF analysis, ROA, debt-to-equity, PE ratio, and price-to-book all register “Strong Sell” signals.

Technical indicators show mixed signals despite the price surge. The Relative Strength Index (RSI) sits at 54.60, indicating neutral momentum. The Stochastic oscillator reads 83.16 on the %K line, suggesting overbought conditions. Money Flow Index (MFI) of 60.17 indicates moderate buying pressure. However, the Average Directional Index (ADX) of 16.53 confirms no established trend, meaning the 9900% move lacks directional conviction. Investors should recognize this as a penny stock prone to extreme volatility rather than a fundamental turnaround.

Final Thoughts

ENDV stock’s 9900% gain on May 7, 2026, reflects the extreme volatility characteristic of penny stocks trading on the PNK exchange rather than meaningful business improvement. Endonovo Therapeutics continues facing severe financial headwinds including negative earnings, depleted working capital, and minimal revenue generation. The company’s Electroceutical technology for regenerative medicine remains promising conceptually, but execution challenges persist. Meyka AI rates ENDV with a C- grade and \”Strong Sell\” recommendation, factoring in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.